Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cue Biopharma Inc
(NQ:
CUE
)
0.7225
+0.0015 (+0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cue Biopharma Inc
< Previous
1
2
3
4
Next >
The Truth About IPO Investing
September 02, 2023
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
August 30, 2023
The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
August 02, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Where Cue Biopharma Stands With Analysts
June 15, 2023
Via
Benzinga
Cue Biopharma Earnings Perspective: Return On Capital Employed
March 22, 2023
Via
Benzinga
3 Biotech Stocks to Buy as Companies Ink Major Deals
June 22, 2023
Pharmaceutical and biotech companies will soon face generic competition, creating big opportunity for these top biotech stocks to buy.
Via
InvestorPlace
Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
June 14, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Host Investor Call
June 07, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma's Earnings Outlook
March 20, 2023
Via
Benzinga
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
June 05, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
3 Biotech Stocks Sitting on Huge-Upside Catalysts
May 26, 2023
The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks.
Via
InvestorPlace
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
May 08, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
7 Hot Growth Stocks Poised to Triple in 2023
May 05, 2023
These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher.
Via
InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
May 04, 2023
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.
Via
InvestorPlace
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
April 25, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
April 12, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 21, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 21, 2023
March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million.
Via
Benzinga
Cue Biopharma to Host Business Update Call and Webcast
March 15, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
March 01, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
February 22, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
February 16, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
February 16, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
February 01, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Chief Medical Officer Transition
January 23, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
November 22, 2022
From
Cue Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.